Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 14 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ublituximab for treating multiple sclerosis	Ublituximab (TG-1101; LFB-R603)	Multiple sclerosis (MS)	Neurology	2022	View \| Download
Tolebrutinib for treating relapsing multiple sclerosis	Tolebrutinib (PRN-2246;SAR-442168)	Multiple sclerosis (MS)	Neurology	2023	View \| Download
Tolebrutinib for treating relapsing and progressive forms of multiple sclerosis	Tolebrutinib (PRN-2246;SAR-442168)	Multiple sclerosis (MS)	Neurology	2023	View \| Download
Ponesimod for Relapsing-remitting Multiple Sclerosis	Ponesimod (ACT-128800; RG-3477)	Multiple sclerosis (MS)	Neurology	2017	View \| Download
Ofatumumab for relapsing multiple sclerosis	Ofatumumab (Arzerra)	Multiple sclerosis (MS)	Neurology	2019	View \| Download
Ocrelizumab (subcutaneous) for the treatment of primary progressive or relapsing multiple sclerosis	Ocrelizumab (Ocrevus;2H7v114)	Multiple sclerosis (MS)	Neurology	2023	View \| Download
Natalizumab biosimilar for treating relapsing-remitting multiple sclerosis	Natalizumab biosimilar (PB006)	Multiple sclerosis (MS)	Neurology	2022	View \| Download
Natalizumab (subcutaneous injection) for highly active relapsing remitting multiple sclerosis	Natalizumab (BG00002; Tysabri; Antegren; AN-100226; ELND-002)	Multiple sclerosis (MS)	Neurology	2021	View \| Download
Glatiramer Acetate Depot for treating relapsing forms of multiple sclerosis in adults aged 18 to 55 years	Glatiramer Acetate Depot (Copaxone)	Multiple sclerosis (MS)	Nephrology	2022	View \| Download
Fingolimod (Gilenya) oral formulation for multiple sclerosis in paediatric patients (aged 10 – 17 years)	Fingolimod (Gilenya; FTY720; fingolimod hydrochloride)	Multiple sclerosis (MS)	Neurology	2017	View \| Download